Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy
Terminated
- Conditions
- Health Care CostPost Partum Haemorrhage
- Registration Number
- NCT02900690
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
The main objective of this project is to assess the average cost of the treatment of bleeding postpartum with recombinant activated factor VII (NovoSeven®) and compare it to the reference strategy. Costs related to medicine NovoSeven® can generate surplus, but it also avoids in some cases very costly invasive procedures. It will be interesting to compare the average cost of the complete strategies supported.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 84
Inclusion Criteria
- Severe haemorrhage is defined by the following criteria: blood loss greater than 1500 ml graduated measured in the bag and / or hemodynamically unstable and / or requiring transfusion of packed red blood cells (3);
- Sulprostone (Nalador®) ineffective;
- Age over 18 years;
- The term is more than 27 SA (child's viability);
- Without anthropomorphic limit;
- The outcome of the pregnancy is normal or pathological;
- Informed consent "emergency procedure" is signed by the husband or family.
Exclusion Criteria
- minors, majors in guardianship, with a personal history of venous or arterial thrombosis may cons-indicate treatment with rFVIIa or refuses to sign the consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method direct medical cost day 1
- Secondary Outcome Measures
Name Time Method